Skip to main content

Cardiovascular outcomes


03-19-2018 | Obesity | News

Further evidence challenges obesity paradox

UK Biobank data add to the evidence challenging the existence of the obesity paradox by showing that cardiovascular disease risk increases linearly with increasing adiposity in middle-aged men and women.

03-15-2018 | Type 2 diabetes | News

Early diabetes onset linked to increased mortality risk

Study results presented at the 2018 Diabetes UK Professional Conference in London confirm that people who are diagnosed with type 2 diabetes at a younger age have an increased mortality risk.

03-11-2018 | Sodium-glucose cotransporter-2 inhibitors | News

CVD-REAL 2 extends SGLT2 inhibitor benefits beyond US and European populations

The latest analysis from the CVD-REAL 2 investigators shows reduced cardiovascular risk associated with sodium-glucose cotransporter 2 inhibitor use among diabetes patients from Asia Pacific, North America, and the Middle East.

Read more


11-22-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

11-13-2017 | Specific populations | Interview | Video

Women and diabetes - our right to a healthy future

Editorial Board member Lori Berard addresses 2017's World Diabetes Day theme, providing her insights on the key considerations for managing diabetes in women in this interview with Medicine Matters diabetes.

10-23-2017 | Cardiovascular disorders | Editorial | Article

Diabetes in special situations: Glucagon-like peptide-1 receptor agonist use in acute myocardial infarction

Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of glucagon-like peptide-1 receptor agonists in patients affected by acute myocardial infarction.

In depth

10-17-2017 | Glucagon-like peptide-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

08-22-2017 | Canagliflozin | Podcast | Audio

Dissecting the CANVAS trial

Listen to editorial board members and CANVAS investigators Carol Wysham and Lori Berard discussing the efficacy and safety findings of the trials.

Journal articles and book chapters

02-05-2018 | Cardiovascular disorders | Review | Article

Type 2 diabetes and thiazide diuretics

Scheen AJ. Curr Diab Rep 2018; 18: 6. doi: 10.1007/s11892-018-0976-6

01-28-2018 | Cardiovascular disorders | Review | Article

Blood pressure targets in type 2 diabetes. Evidence against or in favor of an aggressive approach

Mancia G, Grassi G. Diabetologia 2018; 61: 517–525. doi: 10.1007/s00125-017-4537-3

01-05-2018 | Cardiovascular outcomes | Review | Article

Pharmacological prevention of cardiovascular outcomes in diabetes mellitus: Established and emerging agents

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

image credits